<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695080</url>
  </required_header>
  <id_info>
    <org_study_id>258909</org_study_id>
    <secondary_id>2018-005038-39</secondary_id>
    <nct_id>NCT04695080</nct_id>
  </id_info>
  <brief_title>ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis</brief_title>
  <acronym>ChariotMS</acronym>
  <official_title>ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Plymouth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      MS is a chronic inflammatory and degenerative disease of the central nervous system (CNS)&#xD;
      affecting more than 120,000 people in the UK.and 2.5 million people worldwide.&#xD;
&#xD;
      Without disease modifying treatment (DMT),the majority of people with MS (pwMS) will develop&#xD;
      significant disability within 10 years of onset, and 50% will require wheelchair assistance&#xD;
      within 20 years. convenient, highly effective and CNS penetrant DMT for patients with&#xD;
      relapsing multiple sclerosis (pwRMS) administered in short (8-10 days/year over 2 years)&#xD;
      treatment courses.&#xD;
&#xD;
      It effectively depletes B cells, particularly Memory B cells, a likely key mechanism of&#xD;
      disease control in MS. Cladribine is the investigational product in this study as it not&#xD;
      currently used to treat patients with an EDSS of 6.5 - 8.5. This is a multi-centre,&#xD;
      randomised double-blind placebo-controlled phase IIb to test cladribine tablets (MAVENCLADÂ®)&#xD;
      (3.5mg/kg over 24 months) for safety, efficacy, and cost effectiveness, and to advance&#xD;
      mechanistic understanding of its action in people with advanced MS (pwAMS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2021</start_date>
  <completion_date type="Anticipated">July 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 4, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The 9-HPT peg speed (tasks/second) at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>To establish whether there is efficacy superiority of cladribine tablets over placebo in reducing deterioration of upper limb function in pwAMS.&#xD;
To investigate whether cladribine tablets 3.5mg/kg over 24 months is an effective DMT in pwAMS as measured using the 9-hole peg test (9HPT) peg speed at 24 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>9-HPT proportion of patients who do not deteriorate at 24 months</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: EDSS</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>The proportion of the cladribine versus placebo arms with an increase of &gt;=0.5 in EDSS score over 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: ARAT</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>ARAT (Upper Limb Function Test) upper limb function test score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: ABILHAND</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>ABILHAND score for manual ability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: T25ftWT</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>Lower Limb Function: The T25ftWT (Timed 25 foot walk test) will be collected in all pwAMS able to walk the required distance twice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: SLCVA</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>SLCVA (Sloan low contrast letter visual acuity) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: MSIS-29v2</measure>
    <time_frame>Screening, , Month 6, 12, 18 and 24</time_frame>
    <description>MSIS-29v2 (Multiple Sclerosis Impact Scale) quality of life score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: SDMT</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>SDMT (The Symbol Digit Modalities Test) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: NFI-MS</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>NFI-MS (Neurological Fatigue Index-Multiple Sclerosis) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: EuroQoL EQ-5D-5L</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>Cost-utility: Patient's generic health-related quality of life, measured using the EuroQoL EQ-5D-5L and, separately, carer's generic health-related quality of life, measured using the EuroQoL EQ-5D-5L, health and social care and other costs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: EuroQoL EQ-5D-5L</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>Cost-utility: Carer's generic health-related quality of life, measured using the EuroQoL EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: EuroQoL EQ-5D-5L</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>Cost-utility: health and social care and other costs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over 24 months of the study in clinical outcome measure: WPAI-GH</measure>
    <time_frame>Baseline, Month 6, 12, 18 and 24</time_frame>
    <description>WPAI-GH (Work Productivity and Activity Impairment Questionnaire: General Health V2.0 (WPAI:GH) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/occurrence of adverse events</measure>
    <time_frame>Through study completion, an average of 24 months</time_frame>
    <description>Safety:&#xD;
Any AEs/SAEs,&#xD;
Lymphopenia (peripheral blood lymphocyte counts),&#xD;
Severe infections,&#xD;
Malignancies.&#xD;
Pregnancies&#xD;
Special situations (e.g. overdose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preventing loss of brain volume</measure>
    <time_frame>Screening, Month 6 and 24</time_frame>
    <description>(MRI) Change over 24 months of the study in ventricular volume assessed using the VIENA technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preventing loss of brain volume</measure>
    <time_frame>Screening, Month 6 and 24</time_frame>
    <description>(MRI) Change over 24 months in brain volume assessed using the &quot;Structural Image Evaluation, using Normalisation, of Atrophy&quot; (SIENA) technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preventing loss of spinal cord cross sectional area</measure>
    <time_frame>Screening, Month 6 and 24</time_frame>
    <description>(MRI) Change in the total cross-sectional area of spinal cord (at level C2) over 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preventing new focal demyelinating lesions and T2 burden of disease increase.</measure>
    <time_frame>Screening, Month 6 and 24</time_frame>
    <description>(MRI) Total number of new focal demyelinating brain lesions over 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preventing new hypo-intense lesions (&quot;black holes&quot;) on T1 weighted MRI</measure>
    <time_frame>Screening, Month 6 and 24</time_frame>
    <description>(MRI) Total number of new hypo-intense T1 lesions over 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of unblinding</measure>
    <time_frame>Month 24</time_frame>
    <description>To determine the perception of treatment allocation for both participants and trial teams at 24 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To determine if cladribine correlates with memory Bcell count.</measure>
    <time_frame>Screening, Month 12 and 24</time_frame>
    <description>Memory B-Cell (total number and percentage of CD19+ cell count) and its association with upper limb function as measured using 9HPT speed.</description>
  </other_outcome>
  <other_outcome>
    <measure>To determine association between Memory B cell count and 9HPT speed.</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>9HPT speed</description>
  </other_outcome>
  <other_outcome>
    <measure>To determine association between Memory B cell count and 9HPT speed.</measure>
    <time_frame>Screening, Month 6, 12, 18 and 24</time_frame>
    <description>ARAT score</description>
  </other_outcome>
  <other_outcome>
    <measure>To determine association between Memory B cell count, upper limb function and s-NfL level.</measure>
    <time_frame>Screening, Month 12 and 24</time_frame>
    <description>Serum-NfL at 6 and 24 months compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>To determine effects of IMP on cortical and deep grey matter volumes, thalamic, hippocampal and ventricular volumes (VIENA) and slowly expanding (i.e. chronically active) lesions.</measure>
    <time_frame>Screening, Month 6 and 24</time_frame>
    <description>(MRI) Change over 24 months of the study in cortical brain volume</description>
  </other_outcome>
  <other_outcome>
    <measure>To determine effects of IMP on cortical and deep grey matter volumes, thalamic, hippocampal and ventricular volumes (VIENA) and slowly expanding (i.e. chronically active) lesions.</measure>
    <time_frame>Screening, Month 6 and 24</time_frame>
    <description>(MRI) Change over 24 months of the study in thalamic brain volume</description>
  </other_outcome>
  <other_outcome>
    <measure>To determine effects of IMP on cortical and deep grey matter volumes, thalamic, hippocampal and ventricular volumes (VIENA) and slowly expanding (i.e. chronically active) lesions.</measure>
    <time_frame>Screening, Month 6 and 24</time_frame>
    <description>(MRI) Change over 24 months of the study in hippocampal brain volume</description>
  </other_outcome>
  <other_outcome>
    <measure>To determine effects of IMP on cortical and deep grey matter volumes, thalamic, hippocampal and ventricular volumes (VIENA) and slowly expanding (i.e. chronically active) lesions.</measure>
    <time_frame>Screening, Month 6 and 24</time_frame>
    <description>(MRI) Change over 24 months of the study in new slowly expanding/evolving lesions (SELs)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced Multiple Sclerosis</condition>
  <condition>Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cladribine (MAVENCLADÂ®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine (MAVENCLADÂ®)</intervention_name>
    <description>Cladribine (MAVENCLADÂ®) 3.5mg/kg, administered as weight-adjusted 10mg tablets in two treatment courses (12 months apart) lasting 8- 10 days each.&#xD;
Cladribine (MAVENCLADÂ®) 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets.</description>
    <arm_group_label>Cladribine (MAVENCLADÂ®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as weight adjusted tablets in two treatment courses (12 months apart) lasting 8-10 days each.&#xD;
Placebo 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. pwAMS aged 18+ years with an EDSS of 6.5-8.5 (inclusive)&#xD;
&#xD;
          2. History of bowel cancer screening for men and women and cervical and breast cancer&#xD;
             screening for women as per NHS recommended guidelines.&#xD;
             https://www.nhs.uk/conditions/nhs-screening/&#xD;
&#xD;
          3. Ability to complete the 9HPT with either upper limb within 180 seconds. The average&#xD;
             score of both attempts for each hand should be used to assess eligibility.&#xD;
&#xD;
          4. Confirmation of MS diagnosis according to the McDonald Criteria (2017) Thompson et al.&#xD;
             2018)&#xD;
&#xD;
          5. In the judgement of the investigator, evidence of deterioration of upper limb function&#xD;
             during the 2 years running up to the screening date&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with known hypersensitivity to Cladribine of any grade (as per CTCAE&#xD;
             grading system) should be excluded&#xD;
&#xD;
          2. Any uncontrolled diabetes, arterial hypertension and hypercholesterolaemia as&#xD;
             determined by PI or delegated sub-investigator&#xD;
&#xD;
          3. A history of stroke, deep vein or sinus venous thrombosis and/or myocardial infarction&#xD;
&#xD;
          4. Moderate to severe renal impairment (creatinine clearance &lt;60 ml/min)&#xD;
&#xD;
          5. Moderate to severe hepatic impairment (Child-Pugh score &gt;6)&#xD;
&#xD;
          6. Significant comorbidity, e.g. cardiac failure, renal failure, malignancy, or other&#xD;
             health condition that in the view of the PI or delegated sub-investigator precludes&#xD;
             participation&#xD;
&#xD;
          7. Pregnancy including planning to father a child or breastfeeding&#xD;
&#xD;
          8. Body weight less &lt;40kg&#xD;
&#xD;
          9. Unwillingness to use effective contraception throughout the trial period until at&#xD;
             least six months after the last administration of IMP. This is not applicable for&#xD;
             post-menopausal women&#xD;
&#xD;
         10. Acute infection&#xD;
&#xD;
         11. Infection with Human Immunodeficiency Virus 1 and/or 2&#xD;
&#xD;
         12. Active chronic infection (Syphilis, Tuberculosis, Hepatitis)&#xD;
&#xD;
         13. Precancerous condition or previous diagnosis of cancer&#xD;
&#xD;
         14. Total lymphocyte count &lt;1.0*109/mL&#xD;
&#xD;
         15. Seronegativity for varicella zoster IgG, rubella, measles, mumps. Potential&#xD;
             participants who fall in this category may undergo vaccination and can be screened&#xD;
             (again) once full course has been completed.&#xD;
&#xD;
         16. Relapse within six months before screening&#xD;
&#xD;
         17. Inability to complete an MRI (contraindications for MRI, including but not limited to,&#xD;
             MRI non- compatible pacemaker, cochlear implants, intracranial vascular clips, surgery&#xD;
             within 6 weeks of entry in the study, coronary stent implanted within 8 weeks prior to&#xD;
             the time of the intended MRI, severe anxiety or claustrophobia etc.) or&#xD;
             contraindication to Gd administration.&#xD;
&#xD;
         18. Treatment with steroids due to MS relapse/progression within three months of&#xD;
             screening.&#xD;
&#xD;
             pwAMS who fall in this category may undergo a further screening visit once the three&#xD;
             months' window has expired and may be included if no steroid treatment has been&#xD;
             administered in the intervening period.&#xD;
&#xD;
         19. Treatment with any interferon-beta, glatiramer acetate, teriflunomide or&#xD;
             dimethyl-fumarate within three months before screening.&#xD;
&#xD;
         20. Treatment with natalizumab, fingolimod, siponimod, ponesimod, ozanimod (or other&#xD;
             Sphingosine-1-phosphate receptor modulators) within three months of screening.&#xD;
&#xD;
         21. Treatment with azathioprine, methotrexate, or cyclosporine within six months before&#xD;
             screening.&#xD;
&#xD;
         22. pwAMS treated with teriflunomide will need to undergo accelerated elimination of the&#xD;
             compound before being considered (Research and Case Medical Research 2019).&#xD;
&#xD;
         23. Treatment with haematopoietic stem cell transplantation (HSCT), mitoxantrone,&#xD;
             cyclophosphamide, cladribine, alemtuzumab or another B cell depleting compound, such&#xD;
             as rituximab, ocrelizumab, ublitiuximab, ofatumumab, or biosimilars, unless the&#xD;
             participant concerned has a memory B cell level of â¥20% of the CD19+ population in the&#xD;
             peripheral blood. Such a level would normally not be expected earlier than a minimum&#xD;
             of six months after the last drug administration. Participants who underwent such&#xD;
             treatment will therefore have to be tested for their CD19+/CD27+ memory B cell level&#xD;
             at screening.&#xD;
&#xD;
         24. Treatment with fampridine: If they are already on treatment for at least six months,&#xD;
             participants should continue throughout the trial. However, starting continuous&#xD;
             fampridine treatment after signing the consent sheet will lead to exclusion from&#xD;
             treatment with IMP/placebo.&#xD;
&#xD;
         25. Concurrent participation or previous participation within the last 6 months in another&#xD;
             clinical trial of an IMP or medical device.&#xD;
&#xD;
         26. Unable to swallow tablets&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Klaus Schmierer, PhD, FRCP</last_name>
    <phone>+44 (0)20 7882 6246</phone>
    <email>k.schmierer@qmul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harpreet Mangat</last_name>
    <phone>+44 (0)75 9750 0255</phone>
    <email>chariot@qmul.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Belfast Health and Social Care Trust</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Stella Hughs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Gordon Mazibrada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Princess Royal Hospital</name>
      <address>
        <city>Brighton</city>
        <zip>RH16 4EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Leonora Fisniku</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Bristol NHS Trust Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mark Crossburn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiff University Hospital</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Emma Tallantyre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Rowling Clinic, University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Don Mahad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Hairmyres, NHS Lanarkshire</name>
      <address>
        <city>Glasgow</city>
        <zip>G75 8RG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Niall MacDougall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Helen Ford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walton Centre NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Carolyn Young</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1FR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Klaus Schmierer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Robert Brenner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>London</city>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Miriam Mattoscio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George's University Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Liquin Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Richard Nicolas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jeremy Chataway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luton and Dunstable Hospital</name>
      <address>
        <city>Luton</city>
        <zip>LU4 0DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Floriana DeAngelis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Tatiana Mihalova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Plymouth</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jeremy Hobart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Basil Sharrack</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morriston Hospital, Swansea</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Owen Pearson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Progressive multiple sclerosis</keyword>
  <keyword>Advanced multiple sclerosis</keyword>
  <keyword>Upper limb function</keyword>
  <keyword>Cladribine</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Cognition</keyword>
  <keyword>Health Economics</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Neurofilament light chain</keyword>
  <keyword>B cells</keyword>
  <keyword>Lymphocytes</keyword>
  <keyword>Magnetic Resonance Imaging (MRI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

